Sign in

BLSM on Nasdaq

BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc. is an American pharmaceutical preparations company based in San Diego.1 Its shares trade on Nasdaq under the symbol BLSM.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerBLSM on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address10255 Science Center Drive, Suite 200, San Diego, Ca2
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

BlossomHill Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BlossomHill Therapeutics, Inc.

  • BlossomHill Therapeutics, Inc. San Diego, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led BlossomHill Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jingrong Jean Cui2026–now

Chair

  1. Yishan Li2026–now

President

  1. Jingrong Jean Cui2026–now

Chief financial officer

  1. Jason A. Keyes2026–now
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorGEORGE LEE named Jan 2, 2024 to Dec 10, 202513
  • DirectorTIMOTHY STUBBS named Dec 10, 202513
  • DirectorHongbo Lu named Jan 2, 202414

Timeline

  1. Sep 18, 20268-K Results of operations15
  2. Sep 15, 20268-K Regulation FD disclosure16
  3. Aug 10, 20268-K Bylaws or fiscal year changed; Other events17
  4. Aug 6, 2026New chief executive Jingrong Jean Cui becomes CEO3

Calendar

When it reported results

  1. Sep 18, 2026Reported quarterly or annual results15

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

42 filings to the SEC since October 2021: 1 quarterly reports, 3 major events, 22 insider forms, 4 large holders, 2 private raises, 10 other. The latest 20:

  1. Sep 18, 202610-Q EDGAR
  2. Sep 18, 20268-K EDGAR
  3. Sep 15, 20268-K EDGAR
  4. Aug 18, 2026SCHEDULE 13D EDGAR
  5. Aug 17, 2026SCHEDULE 13G EDGAR
  6. Aug 14, 2026SCHEDULE 13G EDGAR
  7. Aug 13, 2026SCHEDULE 13D EDGAR
  8. Aug 12, 20264 EDGAR
  9. Aug 12, 20264 EDGAR
  10. Aug 10, 20264 EDGAR
  11. Aug 10, 20264 EDGAR
  12. Aug 10, 20264 EDGAR
  13. Aug 10, 20264 EDGAR
  14. Aug 10, 20264 EDGAR
  15. Aug 10, 20264 EDGAR
  16. Aug 10, 20264 EDGAR
  17. Aug 10, 20264 EDGAR
  18. Aug 10, 20264 EDGAR
  19. Aug 10, 2026S-8 EDGAR
  20. Aug 10, 20268-K EDGAR

The 42 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 7 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 10, 2026Liptak Vincent PaulGeneral CounselBuy2,200$16.00$35.2KForm 4
Aug 10, 2026Keyes Jason AChief Financial OfficerBuy700$16.00$11.2KForm 4
Aug 10, 2026Schmid John P.DirectorBuy6,000$16.00$96.0KForm 4
Aug 10, 2026Cormorant Private Healthcare Fund VI, LP10% ownerBuy312,500$16.00$5.0MForm 4
Aug 10, 2026GORDON CARL LDirectorBuy625,000$16.00$10.0MForm 4
Aug 10, 2026OrbiMed Capital GP VIII LLCDirectorBuy625,000$16.00$10.0MForm 4
Aug 7, 2026Liptak Vincent PaulGeneral CounselBuy2,500$15.80$39.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 25, 2025Raised $84.2 million in a private offering of equity Form D: 47 investors so far Form D
  2. Dec 28, 2023Raised $88.6 million in a private offering of equity Form D: $100 million offered in all Form D

SEC filer profile

How BlossomHill Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBlossomHill Therapeutics, Inc.1
  • CIK0001839970
  • Employer ID (EIN)85-15787111
  • Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address10255 Science Center Drive, Suite 200, San Diego, CA1
  • Phone858-732-38801
  • Shares outstanding31,784,909 as of Sep 16, 202622
  • On EDGAR sinceJan 11, 20211
  • Filings44 in all: 3 (11), 4 (11), D (4), 8-K (3), SCHEDULE 13D (2), SCHEDULE 13G (2), 10-Q (1), 424B4 (1)1
    All 17 form types

    8-A12B (1), CERT (1), DRS (1), DRS/A (1), EFFECT (1), S-1 (1), S-1/A (1), S-1MEF (1), S-8 (1)

  • Latest filingsQuarterly report (10-Q) Sep 18, 2026
    Latest 8-K (8-K) Sep 18, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22